Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
AssigneeNew York University
InventorsThomas M. Wisniewski, Fernando Goni
Life of this patent
Estimating the term…
Abstract
The present invention is directed to pharmaceutical agents and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.
Claims30
A pharmaceutical agent selected from the group consisting of a polymer of a first peptide comprising an amino acid sequence
- X1aX2aX3aX4aX5aX6aX7aX8aX9aX10aX11aX12aX13a (SEQ ID NO:
- 19), wherein X1a is C, M, S, or G;
- X2a is T, S, or C;
- X3a is K, R, or H;
- X4a is S, T, or C;
- X5a is V, I, or L;
- X6a is R, K, or H;
- X7a is R, K, or H;
- X8a is Q or N;
- X9a is L, I, or V;
- X10a is L, I, or V;
- X11a is D or E;
- X12a is D or E;
- X13a is Q or N;
- a polymer of a second peptide comprising an amino acid sequence X1bX2bX3bX4bX5bX6bX7bX8bX9bX10bX11bX12bX13b (SEQ ID NO:20), wherein X1b is C, M, S, or G;
- X2b is F, Y, or W;
- X3b is Q or N;
- X4b is I, L, or V;
- X5b is F, Y, or W;
- X6b is I, L, or V;
- X7b is Q or N;
- X8b is T, S, or C;
- X9b is N or Q;
- X10b is D or E;
- X11b is R, K, or H;
- X12b is H, R, or K;
- X13b is Y, W, or F;
- and
- a polymer of a fusion peptide comprising the first and/or second peptides.
An isolated first peptide comprising the amino acid sequence of X1aX2aX3aX4aX5aX6aX7aX8aX9aX10aX11aX12aX13a (SEQ ID NO:
- 19), wherein X1a is C, M, S, or G;
- X2a is T, S, or C;
- Xaa is K, R, or H;
- X4a is S, T, or C;
- X5a is V, I, or L;
- X6a is R, K, or H;
- X7a is R, K, or H;
- X5a is Q, or N;
- X9a is L, I, or V;
- X10a is L, I, or V;
- X11a is D or E;
- X12a is D or E;
- X13a is Q or N, with the proviso that the isolated first peptide does not have an amino acid sequence of SEQ ID NO:2.
An isolated second peptide comprising the amino acid sequence X1bX2bX3bX4bX5bX6bX7bX8bX9bX10bX11bX12bX13b (SEQ ID NO:20), wherein X1b is C, M, S or G;
- X2b is F, Y, Or W;
- X3b is Q or N;
- X4b is I, L, Or V;
- X5b is F, Y, Or W;
- X6b is I, L, Or V;
- X7b is Q Or N;
- X8b is T, S, or C;
- X9b is N or Q;
- X10bis D or E;
- X11b is R, K, or H;
- X12b is H, R, or K;
- X13b is Y, W, or F, with the proviso that the isolated second peptide does not have an amino acid sequence of SEQ ID NO:8.
An isolated fusion peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:13, SEQ ID NO:15, and SEQ ID NO:17.
A pharmaceutical agent selected from the group consisting of
- a polymer of a first peptide comprising an amino acid sequence X1aX2aX3aX4aX5aX6aX7aX8aX9aX10aX11aX12aX13a (SEQ ID NO:
- 19), wherein X1a is C;
- X2a is T or S;
- X3a is K, R, or H;
- X4a is S or T;
- X5a is V, I, or L;
- X6a is R or K;
- X7a is R or K;
- X5a is Q or N;
- X9a is L, I, or V;
- X10a is L, I, or V;
- X11a is D or E;
- X12a is D or E;
- X13a is Q or N;
- a polymer of a second peptide comprising an amino acid sequence XibX2bX3bX4bX5bX6bX7bX8bX9bX10bX11bX12bX13b (SEQ ID NO:20), wherein X1b is C;
- X2b is F, Y, or W;
- X3b is Q or N;
- X4b is I or L;
- X5b is F, Y, or W;
- X6b is I or L;
- X7b is Q or N;
- X8b is T or S;
- X9b is N or Q;
- X10b is D or E;
- X11b is K or H;
- X12b is H or K;
- X13b is Y, W, or F;
- and
- a polymer of a fusion peptide comprising the first and/or second peptides.
Dependencies are inferred from the claim text.